Abstract
Skin is the largest organ in the body and is most commonly affected by neoplasms. In the United States only, approximately 1.2 million cases of nonmelanoma skin cancer and 80,000 cases of melanoma are diagnosed annually. A large number of families of genes that regulate apoptosis have been identified in both normal and malignant cells. There is loss of bcl-2 protein expression with increasing tumor progression. The present study was undertaken to determine the presence and possible role of bcl-2 in primary cutaneous malignancies using immunohistochemical technique and was carried in the Department of Pathology, Government Medical College, Srinagar. Fifty surgical specimens were obtained from the surgical pathology files of Department of Pathology. Imnunohistochemical study was performed. Out of the fifty cases included in the present study, only twenty one cases (42.00%) were positive for bcl-2 oncoprotein while as twenty nine cases (58%)-exhibited negativity. Basal cell carcinomas constituted 38.10% of the total positive cases, followed by Malignant Melanoma (28.57%) where as Keratoacanthomas accounted for only 4.76% positive cases. Squamous cell carcinoma and Bowen's disease constituted 14.28% each to the positive cases.
Keywords: Skin cancer, Immunohistochemistry, Srinagar, bcl-2, Apoptosis, Basal cell carcinomas, Malignant Melanoma, Keratoacanthomas, Squamous cell carcinoma, Bowen's disease.
References
1. National tumor register, Lousiana, U.S.A.
2. Wyllie AH. Apoptosis: Cell death in tissue regulation. Journal of pathology 153:313, 1987.
3. Vaux DL, Cory S, et al. bcl-2 gene promotes haematopoietic cell survival to immortalize cell survival. Nature.1988; 335:440-2.
4. Ngan BY, Chen-Levy Z, et al. Expression in non-Hodgkin's lymphoma of the bcl-2 protein associated with t (14; 18) chromosomal translocation. N Engl J Med. 1988 Jun 23; 318(25):1638-44.
5. Hockenbery D, Nunez G, et al. bcl-2 is an integral inner mitochondria! membrane protein that blocks programmed cell death. Nature. 1990 Nov 22; 348(6299):334-6.
6. Nakagawa K, Yamamura K, Maeda S, Ichihashi M. bcl-2 expression in epidermal keratinocytic diseases. Cancer 1994; 74: 1720-4.
7. Saenz-Santa Maria MC, Reed JA, McNutt NS, et al. Immunohistological expression of bcl-2 in melanomas and intradermal nevi. J Cutan Pathol. 1994 Oct; 21(5):393-7.
8. Ramsay JA, From L, Kahn HJ. et al. bcl-2 protein expression in melanocytic neoplasms of the skin. Mod Pathol. 1995 Feb; 8(2):150-4.
9. Tsujimoto Y, Shimizu S. et al. Role of the mitochondrial membrane permeability transition in cell death. Apoptosis. 2006 Nov 21.
10. Wrone-Smith T, Bergstrom J, Quevedo ME, et al. Differential expression of cell survival and cell cycle regulatory proteins in cutaneous squamoproliferative lesions.J Dermatol Sci. 1999 Jan; 19(1):53-67.
11. Chang CH, Tsai RK, Chen GS, et al. Expression of bcl-2, p53 and Ki in arsenical skin cancers. J Cutan Pathol.19980ct; 25(9):457-62.
12. Swanson PE, Fitzpatrick MM,Ritter J H, Glusac E J,et al. Immunohistologic differential diagnosis of basal cell carcinoma, squamous cell carcinoma, and trichoepithelioma in small cutaneous biopsy specimens.J Cutan Pathol. 1998 Mar; 25(3):I53-9.
13. Morales-Ducret CR, van de Rijn M, et al. bcl-2 expression in primary malignancies of the skin. Arch Dermatol. 1995 Aug; 131(8):909-12.
14. Cerroni L, Soyer HP, Kerl H. et al. bcl-2 protein expression in cutaneous malignant melanoma and benign melanocytic nevi. Am J Dermatopathol. 1995 Feb; 17(1):7-11.
15. Van den Oord JJ, Vandeghinste N, De Ley M, et al. bcl-2 expression in human melanocytes and melanocytic tumors. Am J Pathol. 1994 Aug; 145(2):294-300.
16. Sleater JP, Beers BB, Stephens CA, et al. Keratoacanthoma: a deficient squamous cell carcinoma? Study of bcl-2 expression. J Cutan Pathol. 1994 Dec; 21(6):514-9.
DOI: http://dx.doi.org/10.18535/jmscr/v3i10.27
